Luc G T Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4510435/publications.pdf

Version: 2024-02-01

142 papers	18,470 citations	22153 59 h-index	14208 128 g-index
146 all docs	146 docs citations	146 times ranked	27899 citing authors

#	Article	IF	Citations
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
3	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	28.9	1,515
4	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	12.6	834
5	The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 2016, 1, e89829.	5.0	569
6	Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 579.	2.2	430
7	The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. Thyroid, 2013, 23, 885-891.	4.5	414
8	Genetic diversity of tumors with mismatch repair deficiency influences antiâ€“PD-1 immunotherapy response. Science, 2019, 364, 485-491.	12.6	395
9	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	21.4	394
10	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1015.	2.2	359
11	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 2013, 45, 253-261.	21.4	324
12	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
13	Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirusâ€“Associated Oropharyngeal Cancer. Journal of Clinical Oncology, 2011, 29, 739-746.	1.6	295
14	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	30.7	282
15	Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS). Thyroid, 2014, 24, 832-839.	4.5	275
16	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget, 2016, 7, 10051-10063.	1.8	247
17	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
18	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212

#	Article	IF	Citations
19	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine, 2019, 25, 1715-1720.	30.7	194
20	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
21	Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. American Journal of Surgery, 2010, 200, 454-461.	1.8	168
22	Changing Trends in the Incidence of Thyroid Cancer in the United States. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 709.	2.2	162
23	Decision making in the management of recurrent head and neck cancer. Head and Neck, 2014, 36, 144-151.	2.0	153
24	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
25	The role of neoantigens in response to immune checkpoint blockade. International Immunology, 2016, 28, 411-419.	4.0	148
26	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. JAMA Oncology, 2017, 3, 1487.	7.1	146
27	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	21.4	144
28	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
29	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. Journal of the National Cancer Institute, 2018, 110, 1386-1392.	6.3	137
30	Predictors of Survival in Mucosal Melanoma of the Head and Neck. Annals of Surgical Oncology, 2011, 18, 2748-2756.	1.5	132
31	Therapeutic targeting of tumor suppressor genes. Cancer, 2015, 121, 1357-1368.	4.1	132
32	Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer, 2016, 122, 1523-1532.	4.1	128
33	Response Rates to Antiâ€“PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncology, 2021, 7, 739.	7.1	125
34	Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. Annals of Surgical Oncology, 2015, 22, 3996-4001.	1.5	124
35	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirusâ€“Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 9-17.	0.8	121
36	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 2020, 1, 1188-1203.	13.2	114

#	Article	IF	Citations
37	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
38	Tall-Cell Variant of Papillary Thyroid Carcinoma: A Matched-Pair Analysis of Survival. Thyroid, 2010, 20, 153-158.	4.5	107
39	Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus. International Journal of Cancer, 2019, 145, 775-784.	5.1	101
40	FAT1 mutations cause a glomerulotubular nephropathy. Nature Communications, 2016, 7, 10822.	12.8	99
41	Synchronous cancers in patients with head and neck cancer. Cancer, 2013, 119, 1832-1837.	4.1	98
42	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	6.3	98
43	Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer. Thyroid, 2015, 25, 681-687.	4.5	94
44	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19024-19029.	7.1	91
45	First bite syndrome: Incidence, risk factors, treatment, and outcomes. Laryngoscope, 2012, 122, 1773-1778.	2.0	89
46	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research, 2017, 23, 5970-5980.	7.0	89
47	Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes and Control, 2011, 22, 671-679.	1.8	88
48	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2016, 23, 410-415.	1.5	87
49	Predictors of survival and recurrence after temporal bone resection for cancer. Head and Neck, 2012, 34, 1231-1239.	2.0	86
50	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	3.4	78
51	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications, 2017, 8, 1197.	12.8	77
52	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. Cancer Research, 2017, 77, 6365-6374.	0.9	77
53	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiotherapy and Oncology, 2014, 111, 382-387.	0.6	75
54	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clinical Cancer Research, 2020, 26, 2859-2870.	7.0	75

#	Article	IF	Citations
55	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing ActivatingPIK3CAAlterations. Clinical Cancer Research, 2016, 22, 2009-2019.	7.0	70
56	High rates of regional failure in squamous cell carcinoma of the hard palate and maxillary alveolus. Head and Neck, 2011, 33, 824-830.	2.0	69
57	Androgen Receptor Signaling in Salivary Gland Cancer. Cancers, 2017, 9, 17.	3.7	69
58	Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands. American Journal of Surgical Pathology, 2015, 39, 931-938.	3.7	68
59	Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. Cancer, 2015, 121, 1793-1799.	4.1	68
60	Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016. JAMA - Journal of the American Medical Association, 2019, 322, 2440.	7.4	61
61	Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope, 2016, 126, 1556-1561.	2.0	57
62	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. Immunity, 2021, 54, 1037-1054.e7.	14.3	56
63	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling, 2016, 9, ra33.	3.6	54
64	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncology, 2014, 50, 947-955.	1.5	51
65	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
66	Identification of prognostic molecular biomarkers in 157 HPVâ€positive and HPVâ€negative squamous cell carcinomas of the oropharynx. International Journal of Cancer, 2019, 145, 3152-3162.	5.1	48
67	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 112-115.	3.3	47
68	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Oral Oncology, 2019, 96, 140-147.	1.5	46
69	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers, 2020, 12, 1221.	3.7	46
70	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. Cell Reports Medicine, 2020, 1, 100034.	6.5	46
71	The immune microenvironment and expression of PDâ€L1, PDâ€1, PRAME and MHC I in salivary duct carcinoma. Histopathology, 2019, 75, 672-682.	2.9	43
72	Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. Cancer, 2020, 126, 994-1003.	4.1	42

#	Article	IF	Citations
73	Squamous Cell Carcinoma of the Oral Tongue in the Pediatric Age Group. JAMA Otolaryngology, 2010, 136, 697.	1.2	41
74	White adipose tissue inflammation and cancerâ€specific survival in patients with squamous cell carcinoma of the oral tongue. Cancer, 2016, 122, 3794-3802.	4.1	41
75	Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. Surgery, 2019, 165, 17-24.	1.9	41
76	Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma. Cancer, 2020, 126, 1413-1423.	4.1	41
77	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. Journal of Surgical Oncology, 2019, 119, 130-142.	1.7	40
78	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	6.3	38
79	Robotics in otolaryngology and head and neck surgery: Recommendations for training and credentialing: A report of the 2015 AHNS education committee, AAOâ€HNS robotic task force and AAOâ€HNS sleep disorders committee. Head and Neck, 2016, 38, E151-8.	2.0	37
80	Longâ€term regional control in the observed neck following definitive chemoradiation for nodeâ€positive oropharyngeal squamous cell cancer. International Journal of Cancer, 2013, 133, 1214-1221.	5.1	33
81	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. Oncotarget, 2017, 8, 10312-10323.	1.8	31
82	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nature Genetics, 2022, 54, 996-1012.	21.4	30
83	Increases in Thyroid Cancer Incidence and Mortality. JAMA - Journal of the American Medical Association, 2017, 318, 389.	7.4	29
84	The FAT epidemic: A gene family frequently mutated across multiple human cancer types. Cell Cycle, 2013, 12, 1011-1012.	2.6	28
85	Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. Head and Neck, 2016, 38, E1688-94.	2.0	28
86	Host Factors Independently Associated With Prognosis in Patients With Oral Cavity Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 699.	2.2	28
87	Active surveillance for patients with very lowâ€risk thyroid cancer. Laryngoscope Investigative Otolaryngology, 2020, 5, 175-182.	1.5	28
88	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. JAMA Network Open, 2022, 5, e220448.	5.9	26
89	The 3 Bs of cancer care amid the COVIDâ€19 pandemic crisis: â€œBe safe, be smart, be kindâ€â€”A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. Cancer, 2020, 126, 4092-4104.	4.1	24
90	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncology, 2020, 110, 104877.	1.5	22

#	Article	IF	Citations
91	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. Molecular Cancer Research, 2021, 19, 1510-1521.	3.4	20
92	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
93	Augmented realityâ€enhanced navigation in endoscopic sinus surgery: A prospective, randomized, controlled clinical trial. Laryngoscope Investigative Otolaryngology, 2020, 5, 621-629.	1.5	18
94	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. Cancer Research, 2022, 82, 2076-2083.	0.9	18
95	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. Head and Neck, 2016, 38, E1285-93.	2.0	17
96	Letter to the Editor: Reversal in Thyroid Cancer Incidence Trends in the United States, 2000â€“2017. Thyroid, 2020, 30, 1226-1227.	4.5	17
97	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. Npj Precision Oncology, 2022, 6, 23.	5.4	17
98	Mitonuclear genotype remodels the metabolic and microenvironmental landscape of HÃ¼rthle cell carcinoma. Science Advances, 2022, 8, .	10.3	15
99	Ischemic necrosis of the tongue in patients with cardiogenic shock. Laryngoscope, 2010, 120, 1345-1349.	2.0	14
100	Characterizing Relative and Disease-Specific Survival in Early-Stage Cancers. JAMA Internal Medicine, 2020, 180, 461.	5.1	13
101	The head and neck cancer genome in the era of immunotherapy. Oral Oncology, 2021, 112, 105040.	1.5	13
102	HPV Status as Prognostic Biomarker in Head and Neck Cancerâ€"Which Method Fits the Best for Outcome Prediction?. Cancers, 2021, 13, 4730.	3.7	13
103	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. Molecular Cancer Research, 2022, 20, 45-55.	3.4	13
104	Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers. Cancer, 2022, 128, 685-696.	4.1	13
105	Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 406.	2.2	12
106	Racial Disparities in Cancer Presentation and Outcomes: The Contribution of Overdiagnosis. JNCI Cancer Spectrum, 2020, 4, pkaa001.	2.9	12
107	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidenceâ€based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head and Neck, 2019, 41, 843-856.	2.0	10
108	Association Between Implementation of the 2009 American Thyroid Association Guidelines and De-escalation of Treatment for Low-risk Papillary Thyroid Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 1081.	2.2	10

#	Article	IF	Citations
109	Molecular Profiling of Thyroid Nodulesâ€"Are These Findings Meaningful, or Merely Measurable?. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 845.	2.2	10
110	TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	3.0	10
111	The USPSTF Recommendation on Thyroid Cancer Screening. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 755.	2.2	9
112	Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 585.	2.2	9
113	Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. , 2021, 9, e003683.		9
114	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. Oncotarget, 2019, 10, 3835-3839.	1.8	8
115	Nodal disease burden and outcome of medullary thyroid carcinoma. Head and Neck, 2021, 43, 577-584.	2.0	8
116	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. JAMA Oncology, 2022, 8, 1352.	7.1	8
117	A novel tumor: Specimen index for assessing adequacy of resection in early stage oral tongue cancer. Oral Oncology, 2014, 50, 213-220.	1.5	7
118	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. Head and Neck, 2015, 37, 1633-1641.	2.0	7
119	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. Thyroid, 2015, 25, 865-866.	4.5	7
120	Lung Cancer Evolution: Whatâ€™s Immunity Got to Do with It?. Cancer Cell, 2019, 35, 711-713.	16.8	6
121	Human Papillomavirus in Patients With Hypopharyngeal Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2021, , 019459982110045.	1.9	6
122	Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma. Cancers, 2022, 14, 2263.	3.7	6
123	Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. Journal of Surgical Oncology, 2021, 123, 141-148.	1.7	5
124	Disparities and guideline adherence for <scp>HPV</scp> testing among patients with oropharyngeal squamous cell carcinoma, <scp>NCDB,</scp> and <scp>SEER</scp>. Head and Neck, 2021, 43, 2110-2123.	2.0	5
125	Positron Emission Tomographyâ€"Computed Tomography Imaging, Genomic Profile, and Survival in Patients With Head and Neck Cancer Receiving Immunotherapy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 1119-1120.	2.2	4
126	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. Journal of Radiation Oncology, 2013, 2, 285-291.	0.7	3

#	Article	IF	Citations
127	3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset. Cancers, 2021, 13, 5313.	3.7	3
128	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644.	1.4	3
129	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2816.	3.7	3
130	The role of immune surveillance in malignant transformation of benign salivary gland tumors. Oncotarget, 2021, 12, 592-595.	1.8	2
131	Flexible fiberâ€based CO 2 laser vs monopolar cautery for resection of oral cavity lesions: A single center randomized controlled trial assessing pain and quality of life following surgery. Laryngoscope Investigative Otolaryngology, 2021, 6, 690-698.	1.5	2
132	Treatment of Early Stage Tonsil Cancer in the Age of Human Papillomavirusâ€“Associated Malignancies. Otolaryngology - Head and Neck Surgery, 2021, 165, 104-112.	1.9	2
133	Thyroid Cancer Screening After Nuclear Accidents. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 79.	2.2	1
134	Any day, split halfway: Flexibility in scheduling highâ€dose cisplatinâ€”A large retrospective review from a highâ€volume cancer center. International Journal of Cancer, 2021, 149, 139-148.	5.1	1
135	Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): a prospective, randomized, controlled clinical trial. European Archives of Oto-Rhino-Laryngology, 2022, 279, 4505-4514.	1.6	1
136	Nodal Metastases in Pediatric and Adult Acinic Cell Carcinoma of the Major Salivary Glands. Otolaryngology - Head and Neck Surgery, 2022, , 019459982210830.	1.9	1
137	Transorbital embolization of cavernous sinus dural arterio-venous malformations with surgical exposure and catheterization of the superior ophthalmic vein. Interventional Neuroradiology, 2023, 29, 715-724.	1.1	1
138	Association of Study Methods and Industry Sponsorship With Inconsistent Performance of Molecular Assays for Indeterminate Thyroid Nodules. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 101.	2.2	0
139	Immunologische Signatur und Neoantigen-Landschaft von aggressiven SpeicheldrÃ¼senkarzinomen. Laryngo- Rhino- Otologie, 2021, 100, .	0.2	0
140	Immunological Signature and Neoantigene Landscape of aggressive Salivary Gland Cancers. , 2021, 100, .		0
141	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarkerâ€”Reply. JAMA Oncology, 2021, 7, 1245.	7.1	0
142	Cervical Pneumatocele Following Total Thyroidectomy Presenting as an Air Thyrogram. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	2.2	0